Your browser doesn't support javascript.
loading
CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.
Okoye, Afam A; Duell, Derick D; Fukazawa, Yoshinori; Varco-Merth, Benjamin; Marenco, Alejandra; Behrens, Hannah; Chaunzwa, Morgan; Selseth, Andrea N; Gilbride, Roxanne M; Shao, Jason; Edlefsen, Paul T; Geleziunas, Romas; Pinkevych, Mykola; Davenport, Miles P; Busman-Sahay, Kathleen; Nekorchuk, Michael; Park, Haesun; Smedley, Jeremy; Axthelm, Michael K; Estes, Jacob D; Hansen, Scott G; Keele, Brandon F; Lifson, Jeffery D; Picker, Louis J.
Afiliación
  • Okoye AA; Vaccine and Gene Therapy Institute and.
  • Duell DD; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Fukazawa Y; Vaccine and Gene Therapy Institute and.
  • Varco-Merth B; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Marenco A; Vaccine and Gene Therapy Institute and.
  • Behrens H; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Chaunzwa M; Vaccine and Gene Therapy Institute and.
  • Selseth AN; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Gilbride RM; Vaccine and Gene Therapy Institute and.
  • Shao J; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Edlefsen PT; Vaccine and Gene Therapy Institute and.
  • Geleziunas R; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Pinkevych M; Vaccine and Gene Therapy Institute and.
  • Davenport MP; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Busman-Sahay K; Vaccine and Gene Therapy Institute and.
  • Nekorchuk M; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Park H; Vaccine and Gene Therapy Institute and.
  • Smedley J; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
  • Axthelm MK; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Estes JD; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Hansen SG; Gilead Sciences, Inc., Foster City, California, USA.
  • Keele BF; Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, New South Wales, Australia.
  • Lifson JD; Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, New South Wales, Australia.
  • Picker LJ; Vaccine and Gene Therapy Institute and.
J Clin Invest ; 131(8)2021 04 15.
Article en En | MEDLINE | ID: mdl-33630764
ABSTRACT
To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion using a rhesusized anti-CD8ß monoclonal antibody on barcoded SIVmac239 dynamics on stable ART and after ART cessation in rhesus macaques (RMs). Among the RMs with full CD8+ T cell depletion in both blood and tissue, there were no significant differences in the frequency of viral blips in plasma, the number of SIV RNA+ cells and the average number of RNA copies/infected cell in tissue, and levels of cell-associated SIV RNA and DNA in blood and tissue relative to control-treated RMs during ART. Upon ART cessation, both CD8+ T cell-depleted and control RMs rebounded in fewer than 12 days, with no difference in the time to viral rebound or in either the number or growth rate of rebounding SIVmac239M barcode clonotypes. However, effectively CD8+ T cell-depleted RMs showed a stable, approximately 2-log increase in post-ART plasma viremia relative to controls. These results indicate that while potent antiviral CD8+ T cell responses can develop during ART-suppressed SIV infection, these responses effectively intercept post-ART SIV rebound only after systemic viral replication, too late to limit reactivation frequency or the early spread of reactivating SIV reservoirs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Activación Viral / Síndrome de Inmunodeficiencia Adquirida del Simio / Depleción Linfocítica / Virus de la Inmunodeficiencia de los Simios / Linfocitos T CD8-positivos / Antirretrovirales Límite: Animals Idioma: En Revista: J Clin Invest Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Activación Viral / Síndrome de Inmunodeficiencia Adquirida del Simio / Depleción Linfocítica / Virus de la Inmunodeficiencia de los Simios / Linfocitos T CD8-positivos / Antirretrovirales Límite: Animals Idioma: En Revista: J Clin Invest Año: 2021 Tipo del documento: Article